PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8683700-0 1996 Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. nadir 26-31 kallikrein related peptidase 3 Homo sapiens 0-25 9126238-3 1997 The post-treatment nadir levels of PSA that predict best for subsequent freedom from PSA failure are debatable, and many nadir levels have been proposed as targets. nadir 19-24 kallikrein related peptidase 3 Homo sapiens 35-38 8683700-0 1996 Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. nadir 141-146 kallikrein related peptidase 3 Homo sapiens 0-25 31126725-9 2019 Multivariable analysis revealed that for nadir + 2.0, pre-treatment PSA (odds ratio 0.49; 95% confidence interval 0.26-0.97) correlated with PSA bounce. nadir 41-46 kallikrein related peptidase 3 Homo sapiens 68-71 7523340-14 1994 Only patients with nadir levels < 1 ng/ml fared well (5-year incidence of relapse or rising PSA 17%); however, if the pretreatment level exceeded 30 ng/ml, then even a nadir level < 1 ng/ml was associated with a 40% failure rate at 5 years. nadir 19-24 kallikrein related peptidase 3 Homo sapiens 95-98 7690018-8 1993 Prostate specific antigen failure was defined as a rise above normal level or, for patients whose nadir was above 4 ng/ml, an increase of greater than 10% above nadir. nadir 98-103 kallikrein related peptidase 3 Homo sapiens 0-25 7690018-8 1993 Prostate specific antigen failure was defined as a rise above normal level or, for patients whose nadir was above 4 ng/ml, an increase of greater than 10% above nadir. nadir 161-166 kallikrein related peptidase 3 Homo sapiens 0-25 31672485-2 2020 We have previously shown that time to nadir (TTN) of prostate-specific antigen (PSA) is an important prognostic factor in patients from a single center in Northwestern China. nadir 38-43 kallikrein related peptidase 3 Homo sapiens 53-84 31126725-9 2019 Multivariable analysis revealed that for nadir + 2.0, pre-treatment PSA (odds ratio 0.49; 95% confidence interval 0.26-0.97) correlated with PSA bounce. nadir 41-46 kallikrein related peptidase 3 Homo sapiens 141-144 29756298-8 2018 We posit that a cut-off level of prostate-specific antigen nadir 0.43 ng/mL might be considered as an independent predictive factor for prostate-specific antigen biochemical recurrence in high-intensity focused ultrasound patients in multivariate analysis (P < 0.001, hazard ratio 7.39, 95% confidence interval 3.56-15.37), and created a new nadir-related prediction model for biochemical recurrence prediction. nadir 59-64 kallikrein related peptidase 3 Homo sapiens 33-58 30085076-13 2018 Age at implant, time to onset, and 1-year follow-up after an increase in PSA level of >=2 ng/ml above nadir level are useful for distinguishing between biochemical failure and PSA bounce +2. nadir 105-110 kallikrein related peptidase 3 Homo sapiens 73-76 30085076-13 2018 Age at implant, time to onset, and 1-year follow-up after an increase in PSA level of >=2 ng/ml above nadir level are useful for distinguishing between biochemical failure and PSA bounce +2. nadir 105-110 kallikrein related peptidase 3 Homo sapiens 179-182 29756298-8 2018 We posit that a cut-off level of prostate-specific antigen nadir 0.43 ng/mL might be considered as an independent predictive factor for prostate-specific antigen biochemical recurrence in high-intensity focused ultrasound patients in multivariate analysis (P < 0.001, hazard ratio 7.39, 95% confidence interval 3.56-15.37), and created a new nadir-related prediction model for biochemical recurrence prediction. nadir 59-64 kallikrein related peptidase 3 Homo sapiens 136-161 29756298-9 2018 CONCLUSIONS: Postoperative prostate-specific antigen nadir of 0.43 ng/mL can be considered an important predictive factor for biochemical recurrence in primary whole-prostate gland high-intensity focused ultrasound treatment, and the nadir-related prediction model might provide a reference for early salvage treatment. nadir 53-58 kallikrein related peptidase 3 Homo sapiens 27-52 26867889-8 2016 Biochemical recurrence was defined as an increase of 0.1 in prostate-specific antigen (PSA) from posttreatment nadir or an increase in PSA despite treatment. nadir 111-116 kallikrein related peptidase 3 Homo sapiens 60-91 26867889-8 2016 Biochemical recurrence was defined as an increase of 0.1 in prostate-specific antigen (PSA) from posttreatment nadir or an increase in PSA despite treatment. nadir 111-116 kallikrein related peptidase 3 Homo sapiens 87-90 25444980-10 2015 Undetectable nadir ultrasensitive prostate specific antigen after radical prostatectomy confers a low risk of disease recurrence while a detectable nadir above 0.01 ng/ml requires additional measurement and consideration of other risk factors to determine management and avoid overtreatment. nadir 13-18 kallikrein related peptidase 3 Homo sapiens 34-59 26089252-1 2016 PURPOSE: To investigate the clinical outcomes of metastatic prostate cancer patients and the relationship between nadir prostate-specific antigen (PSA) levels and different types of primary androgen deprivation therapy (PADT). nadir 114-119 kallikrein related peptidase 3 Homo sapiens 120-151 10081869-0 1999 Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy. nadir 26-31 kallikrein related peptidase 3 Homo sapiens 0-25 16890642-9 2006 The prostate specific antigen increase from nadir appears to be a more accurate cancer indicator than a doubled value in some patients. nadir 44-49 kallikrein related peptidase 3 Homo sapiens 4-29 16398402-0 2005 Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer. nadir 40-45 kallikrein related peptidase 3 Homo sapiens 14-39 16398402-1 2005 The objective of this study was to analyze the value of the nadir level of prostate-specific antigen (PSA) to predict androgen-independent progression (AIP) in metastatic prostate cancer patients after androgen deprivation therapy. nadir 60-65 kallikrein related peptidase 3 Homo sapiens 75-106 12023133-0 2002 Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. nadir 40-45 kallikrein related peptidase 3 Homo sapiens 14-39 12023133-8 2002 The predictors of improved cause-specific survival were a lower PSA nadir (p = 0.006) and longer interval to nadir from the start of treatment (p = 0.03). nadir 68-73 kallikrein related peptidase 3 Homo sapiens 64-67 12023133-14 2002 The results provide new information regarding disease progression as a function of posttreatment PSA profiles (time to achieve nadir from start of treatment, nadir, and PSADT) and the timing of androgen deprivation for biochemical relapse. nadir 127-132 kallikrein related peptidase 3 Homo sapiens 97-100 10526285-15 1999 When restricting analysis to 643 patients (74%) with >/= 3 years of PSA follow-up, the median nadir level for biochemically controlled patients was 0.6 ng/mL and occurred at a median interval of 1.9 years after RT versus a median nadir level of 1.3 ng/mL (P = 0.002) occurring at a median interval of 1.0 years (P < 0.001) in those patients who experienced biochemical failure. nadir 97-102 kallikrein related peptidase 3 Homo sapiens 71-74 24372730-7 2014 RESULTS: Median prostate-specific antigen nadir level in the eight patients with biopsy-proven local recurrence after initial low-dose rate brachytherapy was 0.75 ng/mL (range 0.39-2.06). nadir 42-47 kallikrein related peptidase 3 Homo sapiens 16-41 9779716-8 1998 Patients with preradiotherapy nadir levels < or = 0.5 ng/mL after 3 months of NAAD experienced a 5-year PSA relapse-free survival rate of 74%, as compared with 40% for patients with higher nadir levels (P < .001). nadir 30-35 kallikrein related peptidase 3 Homo sapiens 107-110 9779716-11 1998 Patients with NAAD-induced PSA nadir levels greater than 0.5 ng/mL before radiotherapy are more likely to develop biochemical failure and may benefit from more aggressive therapies. nadir 31-36 kallikrein related peptidase 3 Homo sapiens 27-30